Insights On CONTRACT PHARMA MANUFACTURING

  1. Linking Clinical Correlates To Cell Therapy Outcomes 6/9/2025

    Streamline cell therapy development by transforming complex cellular characteristics into a predictive, multiparametric metric that guides the selection of high-potential starting material.

  2. Optimizing The Progression Of Biotherapeutic Candidates To FIH Studies 6/9/2025

    Learn actionable strategies that can lead to higher success rates and smarter resource investment, paving the way for a successful path to IND submissions and commercialization.

  3. 5 Key Considerations For Companies Outsourcing Process Development 6/9/2025

    Venture capital in biotech remains strong post-pandemic, especially in cell and gene therapies. Discover five key factors to help companies choose between in-house and outsourced process development strategies.

  4. Utilizing Small-Scale Downstream Studies Across Biologics Manufacturing 6/6/2025

    Small-scale downstream studies play a critical role in enabling efficient, low-risk tech transfer for biologics development.

  5. Lyophilization To Enable Drug Products Containing Labile Molecules 6/6/2025

    Develop lyophilized formulations to overcome stability challenges and significantly extend the shelf life of sensitive therapeutic products.

  6. Injection Site Reaction Screening Methodology 6/6/2025

    Optimize drug formulations for solubility at physiological pH to reduce injection site reactions, enable high-concentration dosing, and enhance patient comfort and compliance.

  7. Fill-Finish Contract Manufacturing: Trends, Challenges, And The Future 6/6/2025

    See why it's important to partner with a CDMO that’s investing in advanced sterile fill-finish capabilities to meet the demands of complex biologics, gene therapies, and mRNA-based products.

  8. Navigating OOX Results: Effective Analysis, Management In CDMO Labs 6/5/2025

    By prioritizing the management of Out of Expectation (OOX) results within your CDMO laboratory, learn how you can ensure product integrity, patient safety, and unwavering regulatory compliance.

  9. Strengthen Pharmaceutical Supply Chains With A US-Based CDMO 6/5/2025

    While certain ingredients require sourcing abroad, partnering with a U.S.-based company that owns its manufacturing assets allows for direct oversight of product quality and supply reliability.

  10. The Advantages Of Off-The-Shelf GMP iPSCs With A DMF 6/2/2025

    Learn how off-the-shelf, GMP-grade iPSC lines with a Drug Master File (DMF) can accelerate cell therapy development, streamline regulatory approval, and reduce time and cost to clinic.